Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Immuneering (IMRX) Non-cash Items (2021 - 2022)

Immuneering has reported Non-cash Items over the past 2 years, most recently at $2.7 million for Q4 2022.

Quarterly results put Non-cash Items at $2.7 million for Q4 2022, down 90.17% from a year ago — trailing twelve months through Dec 2022 was $2.7 million (down 90.17% YoY), and the annual figure for FY2022 was $2.7 million, down 90.17%.
Non-cash Items for Q4 2022 was $2.7 million at Immuneering, down from $25.9 million in the prior quarter.
Over the last five years, Non-cash Items for IMRX hit a ceiling of $56.3 million in Q3 2021 and a floor of $2.7 million in Q4 2022.